• 1
    Peters GJ, van der Wilt CL, van Triest B, Codacci-Pisanelli G, Johnston PG, van Groeningen CJ, Pinedo HM. Thymidylate synthase and drug resistance. Eur J Cancer 1995; 31A: 12991305.
  • 2
    Pinedo HM, Peters GF. Fluorouracil: biochemistry and pharmacology. J Clin Oncol 1988; 6: 16531664.
  • 3
    Pickard M, Dive C, Kinsella AR. Differences in resistance to 5-fluorouracil as a function of cell cycle delay and not apoptosis. Br J Cancer 1995; 72: 13891396.
  • 4
    Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993; 74: 957967.
  • 5
    Sharma R, Adam E, Schumacher U. The action of 5-fluorouracil on human HT29 colon cancer cells grown in SCID mice: mitosis, apoptosis and cell differentiation. Br J Cancer 1997; 76: 10111016.
  • 6
    Huschtscha LI, Bartier WA, Ross CE, Tattersall MH. Characteristics of cancer cell death after exposure to cytotoxic drugs in vitro. Br J Cancer 1996; 73: 5460.
  • 7
    Yang B, Eshleman JR, Berger NA, Markowitz SD. Wild-type p53 protein potentiates cytotoxicity of therapeutic agents in human colon cancer cells. Clin Cancer Res 1996; 2: 16491657.
  • 8
    Johnston PG, Lenz HJ, Leichman CG, Danenberg KD, Allegra CJ, Danenberg PV, Leichman L. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 1995; 55: 14071412.
  • 9
    Lenz HJ, Danenberg KD, Leichman CG, Florentine B, Johnston PG, Groshen S, Zhou L, Xiong YP, Danenberg PV, Leichman LP. p53 and thymidylate synthase expression in untreated stage II colon cancer: associations with recurrence, survival, and site. Clin Cancer Res 1998; 4: 12271234.
  • 10
    Kuniyasu T, Nakamura T, Tabuchi Y, Kuroda Y. Immunohistochemical evaluation of thymidylate synthase in gastric carcinoma using a new polyclonal antibody: the clinical role of thymidylate synthase as a prognostic indicator and its therapeutic usefulness. Cancer 1998; 83: 13001306.
  • 11
    Romain S, Martin PM, Klijn JG, van Putten WL, Look MP, Guirou O, Foekens JA. DNA-synthesis enzyme activity: a biological tool useful for predicting anti-metabolic drug sensitivity in breast cancer? Int J Cancer 1997; 74: 156161.
  • 12
    Findlay MPN, Cunningham D, Morgan G, Clinton S, Hardcastle A, Aherne GW. Lack of correlation between thymidylate synthase levels in primary colorectal tumours and subsequent response to chemotherapy. Br J Cancer 1997; 75: 903909.
  • 13
    Johnston PG, Fisher ER, Rockette HE, Fisher B, Wolmark N, Drake JC, Chabner BA, Allegra CJ. The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol 1994; 12: 26402647.
  • 14
    Aschele C, Debernardis D, Casazza S, Antonelli G, Tunesi G, Baldo C, Lionetto R, Maley F, Sobrero A. Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy. J Clin Oncol 1999; 17: 17601770.
  • 15
    Etienne MC, Pivot X, Formento JL, Bensadoun RJ, Formento P, Dassonville O, Francoual M, Poissonnet G, Fontana X, Schneider M, Demard F, Milano G. A multifactorial approach including tumoural epidermal growth factor receptor, p53, thymidylate synthase and dihydropyrimidine dehydrogenase to predict treatment outcome in head and neck cancer patients receiving 5-fluorouracil. Br J Cancer 1999; 79: 18641869.
  • 16
    Etienne MC, Cheradame S, Fischel JL, Formento P, Dassonville O, Renee N, Schneider M, Thyss A, Demard F, Milano G. Response to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activity. J Clin Oncol 1995; 13: 16631670.
  • 17
    van Triest B, Pinedo HM, van Hensbergen Y, Smid K, Telleman F, Schoenmakers PS, van der Wilt CL, van Laar JA, Noordhuis P, Jansen G, Peters GJ. Thymidylate synthase level as the main predictive parameter for sensitivity to 5-fluorouracil, but not for folate-based thymidylate synthase inhibitors, in 13 nonselected colon cancer cell lines. Clin Cancer Res 1999; 5: 643654.
  • 18
    Mirjolet JF, Barberi Heyob M, Merlin JL, Marchal S, Etienne MC, Milano G, Bey P. Thymidylate synthase expression and activity: relation to S-phase parameters and 5-fluorouracil sensitivity. Br J Cancer 1998; 78: 6268.
  • 19
    Mirjolet JF, Barberi Heyob M, Didelot C, Peyrat JP, Abecassis J, Millon R, Merlin JL. Bcl-2/Bax protein ratio predicts 5-fluorouracil sensitivity independently of p53 status. Br J Cancer 2000; 83: 13801386.
  • 20
    Nita ME, Nagawa H, Tominaga O, Tsuno N, Fujii S, Sasaki S, Fu CG, Takenoue T, Tsuruo T, Muto T. 5-Fluorouracil induces apoptosis in human colon cancer cell lines with modulation of Bcl-2 family proteins. Br J Cancer 1998; 78: 986992.
  • 21
    Wilson GD. Assessment of human tumour proliferation using bromodeoxyuridine—current status. Acta Oncol 1991; 30: 903910.
  • 22
    Begg AC, McNally NJ, Shrieve DC, Karcher H. A method to measure the duration of DNA synthesis and the potential doubling time from a single sample. Cytometry 1985; 6: 620626.
  • 23
    Gratzner HG. Monoclonal antibody to 5-bromo- and 5-iododeoxyuridine: a new reagent for detection of DNA replication. Science 1982; 218: 474475.
  • 24
    Holdaway KM, Finlay GJ, Baguley BC. Relationship of cell cycle parameters to in vitro and in vivo chemosensitivity for a series of Lewis lung carcinoma lines. Eur J Cancer 1992; 28A: 14271431.
  • 25
    Bolger BS, Symonds RP, Stanton PD, MacLean AB, Burnett R, Kelly P, Cooke TG. Prediction of radiotherapy response of cervical carcinoma through measurement of proliferation rate. Br J Cancer 1996; 74: 12231226.
  • 26
    Corvo R, Giaretti W, Sanguineti G, Geido E, Orecchia R, Guenzi M, Margarino G, Bacigalupo A, Garaventa G, Barbieri M, et al. In vivo cell kinetics in head and neck squamous cell carcinomas predicts local control and helps guide radiotherapy regimen. J Clin Oncol 1995; 13: 18431850.
  • 27
    Vuckovic J, Forenpoher G, Marusic M, Uzarevic B, Zemunik T. Prognostic relevance of non-Hodgkin's lymphomas cell cycle data. Neoplasma 1998; 45: 332335.
  • 28
    Wenger CR, Clark GM. S-phase fraction and breast cancer—a decade of experience. Breast Cancer Res Treat 1998; 51: 255265.
  • 29
    Chou TC, Talalay P. Application of the median-effect principle for the assessment of low dose risk of carcinogens and for the quantitation of synergism and antagonism of chemotherapeutic agents. In: HarrapKR, ConnorsTA, editors. New avenues in developmental cancer chemotherapy. New York: Academic Press; 1987. p 3764.
  • 30
    Marchal S, Marchal C, Parache RM, Benjaafar N, Odda M, Leclerc A, Merlin JL, el Gueddarri B, Bey P. Combined flow cytometry and immunohistochemistry analyses for the assessment of nasopharyngeal carcinoma cell kinetics by in vivo bromodeoxyuridine infusion. Cytometry 1997; 29: 165172.
  • 31
    Pestalozzi BC, Peterson HF, Gelber RD, Goldhirsch A, Gusterson BA, Trihia H, Lindtner J, Cortes-Funes H, Simmoncini E, Byrne MJ, Golouh R, Rudenstam CM, Castiglione-Gertsch M, Allegra CJ, Johnston PG. Prognostic importance of thymidylate synthase expression in early breast cancer. J Clin Oncol 1997; 15: 19231931.
  • 32
    Samsonoff WA, Reston J, McKee M, O'Connor B, Galivan J, Maley G, Maley F. Intracellular location of thymidylate synthase and its state of phosphorylation. J Biol Chem 1997; 272: 1328113285.
  • 33
    Poon PP, Storms RK. Thymidylate synthase is localized to the nuclear periphery in the yeast Saccharomyces cerevisiae. J Biol Chem 1994; 269: 83418347.
  • 34
    Horie N, Aiba H, Oguro K, Hojo H, Takeishi K. Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5′-terminal regulatory region of the human gene for thymidylate synthase. Cell Struct Funct 1995; 20: 191197.
  • 35
    Berger SH, Barbour KW, Berger FG. A naturally occurring variation in thymidylate synthase structure is associated with a reduced response to 5-fluoro-2'-deoxyuridine in a human colon tumor cell line. Mol Pharmacol 1988; 34: 480484.
  • 36
    Johnson LF. Posttranscriptional regulation of thymidylate synthase gene expression. J Cell Biochem 1994; 54: 387392.
  • 37
    Ayusawa D, Shimizu K, Koyama H, Kaneda S, Takeishi K, Seno T. Cell-cycle-directed regulation of thymidylate synthase messenger RNA in human diploid fibroblasts stimulated to proliferate. J Mol Biol 1986; 190: 559567.
  • 38
    Begg AC. The clinical status of Tpot as a predictor? Or why no tempest in the Tpot! [editorial; comment]. Int J Radiat Oncol Biol Phys 1995; 32: 15391541.
  • 39
    Haustermans K, Fowler J, Geboes K, Christiaens MR, Lerut A, van der Schueren E. Relationship between potential doubling time (Tpot), labeling index and duration of DNA synthesis in 60 esophageal and 35 breast tumors: is it worthwhile to measure Tpot? Radiother Oncol 1998; 46: 157167.
  • 40
    Zackrisson B, Gustafsson H, Stenling R, Flygare P, Wilson GD. Predictive value of potential doubling time in head and neck cancer patients treated by conventional radiotherapy. Int J Radiat Oncol Biol Phys 1997; 38: 677683.
  • 41
    Gilliland R, Williamson KE, Hamilton PW, Crockard A, Spence RA. DNA denaturation sensitivity may invalidate bromodeoxyuridine—DNA flow cytometric analysis of potential doubling times in colorectal tumours. Br J Surg 1997; 84: 242247.
  • 42
    Haustermans K, Hofland I, Pottie G, Ramaekers M, Begg AC. Can measurements of potential doubling time (Tpot) be compared between laboratories? A quality control study [see comments]. Cytometry 1995; 19: 154163.
  • 43
    Piazza GA, Rahm AK, Finn TS, Fryer BH, Li H, Stoumen AL, Pamukcu R, Ahnen DJ. Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction. Cancer Res 1997; 57: 24522459.
  • 44
    Tsurusawa M, Niwa M, Katano N, Fujimoto T. Flow cytometric analysis by bromodeoxyuridine/DNA assay of cell cycle perturbation of methotrexate-treated mouse L1210 leukemia cells. Cancer Res 1988; 48: 42884293.
  • 45
    Tonkinson JL, Marder P, Andis SL, Schultz RM, Gossett LS, Shih C, Mendelsohn LG. Cell cycle effects of antifolate antimetabolites: implications for cytotoxicity and cytostasis. Cancer Chemother Pharmacol 1997; 39: 521531.
  • 46
    Sheaff RJ, Roberts JM. Regulation of G1 phase. Results Probl Cell Differ 1998; 22: 134.